临床药师对1例IVIG无反应型川崎病合并冠状动脉瘤患儿的用药监护  

Pharmaceutical Case of Clinical Pharmacist for a Child with IVIG Unresponsive Kawasaki Disease and Coronary Aneurysm

作　　者：何大方[1] 张娴[2] 袁勇 He Dafang;Zhang Xian;Yuan Yong(Department of Pharmacy,Institute of Maternal and Children Hygiene of Kunming,Kunming 650031,China;Department of Pediatrics,the Second Affiliate Hospital of Kunming Medical University)

机构地区：[1]昆明市妇幼保健院药剂科,昆明650031 [2]昆明医科大学第二附属医院儿科

出　　处：《中国药师》2020年第11期2217-2220,共4页China Pharmacist

摘　　要：临床药师参与1例大剂量静脉内免疫球蛋白(IVIG)无反应型川崎病合并冠状动脉瘤的治疗过程,患儿入院后对IVIG无反应型川崎病急性期独立高危风险因素重新评价,再次给予IVIG与甲泼尼龙联用冲击治疗,临床药师协助医师制定川崎病合并冠状动脉瘤个体化抗凝治疗方案,对急性期冲击治疗及冠状动脉病变抗凝治疗过程中药物不良反应进行用药监护。患儿经过治疗后病情恢复平稳,未发生心血管不良事件。临床药师深入临床,协助医师及时调整治疗方案,保障了患儿的用药安全。Clinical pharmacist participated in treating a patient with IVIG unresponsive Kawasaki disease with coronary aneurysm.After re-evaluating the independent high-risk risk factors for the acute phase of IVIG non-responsive Kawasaki disease,IVIG combined with methylprednisolone was given assisting physicians in formulating individual anticoagulation treatment plan for Kawasaki disease combined with coronary aneurysm,and medication monitoring was carried out for adverse drug reactions during acute phase shock treatment and coronary artery disease anticoagulation treatment.After treatment,the patient returned to a stable condition and no cardiovascular adverse event occurred.Clinical pharmacist goes deep into clinic and assists doctor in adjusting treatment plans in time to ensure the safety of children’s medication.

关 键 词：临床药师 川崎病 大剂量静脉内免疫球蛋白无反应型 药学监护 

分 类 号：R97[医药卫生—药品]